215 related articles for article (PubMed ID: 34118831)
21. Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
Prelaj A; Bottiglieri A; Bhat G; Washington R; Calareso G; Greco GF; Ferrara R; Brambilla M; De Toma A; Occhipinti M; Manglaviti S; Soro A; Ganzinelli M; Lo Russo G; Proto C
Front Oncol; 2022; 12():902967. PubMed ID: 35756673
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics and their influences on the survival of leptomeningeal metastasis derived from lung adenocarcinoma harboring epithelial growth factor receptor mutation].
Jiang AF; Zhou SS; Zhou Q; Zhao J; Li XP; Zhou RR; Li B
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(34):2713-2719. PubMed ID: 37675543
[No Abstract] [Full Text] [Related]
23. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
[TBL] [Abstract][Full Text] [Related]
24. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
25. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
26. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.
Chiang CL; Lee CC; Huang HC; Wu CH; Yeh YC; Shen CI; Luo YH; Shiao TH; Chang HJ; Huang YT; Chen YM; Chou TY; Chiu CH
Target Oncol; 2021 Mar; 16(2):207-214. PubMed ID: 33566300
[TBL] [Abstract][Full Text] [Related]
27. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
28. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Genomic Features of
Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.
Li N; Liu Y; Duan J; Yang B; Bai H; Sun R; Yu L; Wang J
Thorac Cancer; 2019 Aug; 10(8):1673-1682. PubMed ID: 31368671
[TBL] [Abstract][Full Text] [Related]
31. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
Ge M; Zhan Q; Zhang Z; Ji X; Zhou X; Huang R; Liang X
BMC Cancer; 2019 Feb; 19(1):143. PubMed ID: 30755180
[TBL] [Abstract][Full Text] [Related]
32. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.
Li H; Lin Y; Yu T; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
Ann Palliat Med; 2020 Jul; 9(4):2341-2346. PubMed ID: 32648459
[TBL] [Abstract][Full Text] [Related]
33. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
34. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
35. A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.
Oyamada Y; Wada S; Fujimoto K
Gan To Kagaku Ryoho; 2021 Jun; 48(6):845-847. PubMed ID: 34139737
[TBL] [Abstract][Full Text] [Related]
36. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
37. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
[TBL] [Abstract][Full Text] [Related]
38. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
[TBL] [Abstract][Full Text] [Related]
39. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
[TBL] [Abstract][Full Text] [Related]
40. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R; Prelaj A; Sun S; Baik C; Wollner M; Haura EB; Mamdani H; Riess JW; Cappuzzo F; Garassino MC; Heymach JV; Socinski MA; Leu SY; Bhat G; Lebel F; Le X;
J Thorac Oncol; 2023 Aug; 18(8):1031-1041. PubMed ID: 36958688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
